Estradiol blood test
Estradiol (E2). Also called: E2, Oestradiol, 17-beta estradiol, Sensitive estradiol
Estradiol is the main estrogen. In women it comes mainly from the ovaries and swings through the menstrual cycle; in men it is made from testosterone and is needed for bone and body composition. Low levels need a sensitive (mass-spectrometry) test.
At a glance
| What it measures | Estradiol (E2), the main estrogen, by immunoassay or by more sensitive mass spectrometry. |
|---|---|
| Sample | Blood (serum). Men, children and postmenopausal women should have a sensitive LC-MS/MS test. |
| Typical adult range | Men: 8.0-35.0 pg/mL (Labcorp sensitive), 29 or below (Quest ultrasensitive). Women vary by cycle phase; postmenopausal below 15.0 (Labcorp sensitive). |
| Common reasons it reads high | Ovulation, pregnancy, fertility drugs, ovarian overactivity, and in men extra conversion of testosterone (aromatization), sometimes with breast growth. |
| Peptides that move it | Raised by Human Chorionic Gonadotropin (hCG) (men), HMG (Human Menopausal Gonadotropin) and pulsatile Gonadorelin. Lowered to postmenopausal levels by Leuprolide, Triptorelin, Goserelin and Nafarelin after an initial rise. |
| Lab code | LOINC 2243-4 (immunoassay); 35384-7 high sensitivity (Labcorp 140244, Quest 30289) |
What is Estradiol?
Estradiol regulates the menstrual cycle and maintains female sex characteristics, and it also matters for growth, bone metabolism and blood vessels in both sexes. In women it reflects ovarian function; in men, high levels can come from increased aromatization (conversion) of androgens and cause breast growth (gynecomastia).
Labcorp's standard immunoassay is designed for fertility testing in women of reproductive age. For children, postmenopausal women and men, whose levels are much lower, Labcorp recommends its sensitive LC-MS/MS test.
How it is made and regulated
Where it is made
In women most estradiol comes from the ovaries, so levels drop with ovarian failure and menopause. In men it is made from androgens by aromatization.
Sources: [2]
What controls it
Estradiol follows the menstrual cycle, peaking before ovulation, and fluctuates dramatically during the perimenopausal transition, overlapping with values seen in normal cycles.
How it travels in the blood
In blood, estradiol is carried by SHBG, which binds it with medium affinity (more loosely than testosterone). When SHBG rises, as in liver cirrhosis in men, the balance shifts toward estradiol.
How long it lasts
After a transdermal estradiol patch was removed in postmenopausal women, estradiol fell with a mean half-life of 161 minutes (range 107-221), longer in heavier women.
Sources: [6]
What it does
In men, estrogen matters too: when estradiol was removed experimentally, estrogen deficiency mainly increased body fat and contributed to lower sexual function, and estradiol above 10 pg/mL was generally enough to prevent bone loss.
Reference ranges
Estradiol ranges depend on sex, age, cycle phase and, critically, the method. Each lab has a standard immunoassay and a sensitive mass-spectrometry (LC-MS/MS) test, with different ranges.
Labcorp (test 004515)
| Group | Range (pg/mL) |
|---|---|
| Adult men | 7.6-42.6 |
| Women, follicular phase | 12.5-166.0 |
| Women, ovulation | 85.8-498.0 |
| Women, luteal phase | 43.8-211.0 |
| Women, postmenopausal | Below 6.0 to 54.7 |
| Pregnancy, first trimester | 215.0 to above 4300.0 |
Children and teens
| Group | Range (pg/mL) |
|---|---|
| Boys, 1 to 10 years | 0.0-20.0 |
| Girls, 1 to 10 years | 6.0-27.0 |
Standard immunoassay, designed for fertility testing in women of reproductive age. No CDC HoSt certification claim found in lab documentation (CDC's own participants list returns 403 and could not be verified).
Labcorp (test 140244)
| Group | Range (pg/mL) |
|---|---|
| Adult men | 8.0-35.0 |
| Women, follicular phase | 30.0-100.0 |
| Women, luteal phase | 70.0-300.0 |
| Women, postmenopausal | Below 15.0 |
Children and teens
| Group | Range (pg/mL) |
|---|---|
| Prepubertal children | Below 15.0 |
| Boys, Tanner stages 4-5 | 10.0-36.0 |
| Girls, Tanner stage 5 | 34.0-170.0 |
Sensitive test recommended for men, children and postmenopausal women. No CDC HoSt certification claim found in lab documentation (CDC's own participants list returns 403 and could not be verified).
Quest Diagnostics (test 4021)
| Group | Range (pg/mL) |
|---|---|
| Men | 39 or below |
| Women, follicular phase | 30-144 |
| Women, mid-cycle | 64-357 |
| Women, luteal phase | 56-214 |
| Women, postmenopausal | 31 or below |
Standard immunoassay; Quest recommends test 30289 when low levels are expected. No CDC HoSt certification claim found in lab documentation (CDC's own participants list returns 403 and could not be verified).
Quest Diagnostics (test 30289)
| Group | Range (pg/mL) |
|---|---|
| Men | 29 or below |
| Women, follicular phase | 39-375 |
| Women, luteal phase | 48-440 |
| Women, postmenopausal | 10 or below |
Children and teens
| Group | Range (pg/mL) |
|---|---|
| Boys, 15-17 years | 31 or below |
| Girls, 15-17 years | 283 or below |
Ultrasensitive test; Quest also lists ranges for younger children. No CDC HoSt certification claim found in lab documentation (CDC's own participants list returns 403 and could not be verified).
No CDC HoSt certification claim found in lab documentation (CDC's own participants list returns 403 and could not be verified). Quest recommends its ultrasensitive LC-MS test for anyone expected to have low estradiol, including men, children and hypogonadal or postmenopausal women; Labcorp says the same for its sensitive test. Quest's ranges are for its East region.
Is there an "optimal" range?
The bigger question for estradiol is often not the target but whether the number can be trusted at low levels. For men there is no agreed optimal level, though too little clearly causes harm.
Immunoassays are unreliable at low levels
Endocrine Society position statement (2013)
Very low estradiol levels, which matter outside reproduction, are too low to be measured accurately or precisely with routine methods; better assays and standardization are needed.
Sources: [10]
Most assays fail at low levels
Most assays cannot measure below 10 pg/mL
Comparison of 11 immunoassays and 6 mass-spectrometry methods (2014)
Only 3 of 17 assays met performance criteria, and most could not measure estradiol below 10 pg/mL.
Sources: [11]
Men need some estradiol
Above 10 pg/mL generally protected bone
Finkelstein and colleagues, men given goserelin with graded testosterone, with or without an aromatase inhibitor (2013, 2016)
Estrogen deficiency mainly increased body fat and contributed to lower sexual function; estradiol above 10 pg/mL and testosterone above 200 ng/dL were generally enough to prevent bone loss.
What raises it
| Factor | How | How much |
|---|---|---|
| Ovulation, pregnancy and fertility treatmentPhysiology | Estradiol peaks before ovulation and is very high in pregnancy and during ovulation induction for assisted reproduction. | Labcorp first trimester: 215.0 to above 4300.0 pg/mL [1] [2] |
| Ovarian overactivityCondition | Primary or secondary ovarian hyperfunction raises estradiol in women. | No published magnitude [2] |
| Aromatization in menPhysiology | Increased conversion of androgens to estradiol raises it in men and can cause breast growth. | No published magnitude [2] |
| Liver cirrhosis (men)Condition | Men with cirrhosis had higher estradiol, alongside raised SHBG. | 152 vs 96 pmol/L [5] |
| hCG, hMG and pulsatile GnRHPeptide | These stimulate the gonads. See the peptide table below. | hCG in men: estradiol +168% 24 hours after the first injection [12] [13] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Menopause and ovarian failurePhysiology | Lack of ovarian estradiol production (primary ovarian hypofunction or menopause) lowers it. | Quest ultrasensitive postmenopausal: 10 pg/mL or below [2] [9] |
| Pituitary or hypothalamic diseaseCondition | A lesion in the hypothalamus or pituitary removes the drive to the ovaries (secondary ovarian hypofunction). | No published magnitude [2] |
| Hard aerobic exerciseLifestyle | In premenopausal women training 300 minutes a week, estrogen exposure across the cycle fell, mostly in the luteal phase. A milder 150-minute-a-week program did not change it. | Total estrogen exposure -18.9% [14] [15] |
| Long-term opioids (men)Medication | Estradiol was subnormal in 74% of men taking sustained-action opioids. | No published magnitude [16] |
| GnRH agonistsPeptide | After a short initial rise, continuous dosing cuts estradiol to postmenopausal levels. See the peptide table below. | Leuprolide: postmenopausal concentrations within two to four weeks [17] |
Peptides that affect Estradiol
How each peptide in our library has been shown to affect estradiol, strongest evidence first. GnRH agonists are listed as "lowers", but each first causes a short rise; the size column gives both. Most studies did not say which assay they used. "No clear effect" means estradiol was measured and did not change.
| Peptide | Effect on Estradiol | Size of effect | Evidence |
|---|---|---|---|
| Gonadorelin | Raises | Same 5 women, pulsatile gonadorelin: estradiol 58 to 260 pmol/L after 1 week (P=0.011); assay not statedPulsatile gonadorelin restored ovarian estradiol production in women with hypogonadotropic hypogonadism. [18] | Human trials |
| HMG (Human Menopausal Gonadotropin) | Raises | Single dose (2 ampules) in women (acute): estradiol peaked at 18 hours, +75.4% in PCOS and +88.5% in ovulatory women; assay not statedhMG stimulates the ovaries and raised estradiol within a day in women with and without PCOS. [19] | Human trials |
| Human Chorionic Gonadotropin (hCG) | Raises | Acute: 23 men with suspected primary hypogonadism, daily hCG injections: estradiol peaked 24 hours after the first injection (+168%, p=0.001). Sustained: men with testosterone above 300 ng/dL on hCG twice weekly, 27.5 to 32 pg/mL (not significant); assay not statedhCG raises estradiol quickly by stimulating the testes; in longer-term use in men with normal testosterone the rise was small and not significant. [12] [13] | Human trials |
| Leptin | Raises | Same 8 women with hypothalamic amenorrhea, recombinant human leptin for up to three months: estradiol rose with follicle development; assay not stated, no values in the abstractEstradiol rose as ovarian follicles developed during leptin replacement in women with hypothalamic amenorrhea. [20] | Human trials |
| Buserelin | Lowers | Women: in 20 women with polycystic ovaries (200 micrograms s.c. 3 times daily), the first injection raised 17 beta-oestradiol; in women on 1200 micrograms/day intranasally (30 starting on cycle day 1, 22 in the luteal phase), ovarian estradiol was suppressed during the first 10-14 days (assay not stated)Estradiol rises briefly after the first dose, then is suppressed within about two weeks of continued use. [21] [22] | Human trials |
| Tirzepatide | Lowers | Men with obesity and metabolic hypogonadism, tirzepatide 2.5 mg weekly for the first month then 5 mg, plus diet and walking, 2 months (28 men; controls: lifestyle only or testosterone gel), electrochemiluminescence immunoassay: estradiol median 33.0 to 11.0 pg/mL, lower than both control groupsA 2-month pilot in 28 men with obesity and low testosterone, not randomized: estradiol fell as testosterone rose and weight dropped. [23] | Human trials |
| Octreotide | No clear effect | Nine insulin-dependent diabetic women, 100 micrograms twice daily for 7 days: no significant fall in ovarian steroids, including estradiol; assay not statedOne small study in women found no significant estradiol change. [24] | Human trials |
| Oxytocin | No clear effect | Sixty-one adults with obesity (52% women), intranasal oxytocin 24 IU four times daily vs placebo for eight weeks (sustained): estradiol not affected (week 8: 156.5 vs 115.6 pg/mL; p ≥ 0.458); assay not statedEight weeks of intranasal oxytocin did not change estradiol in a placebo-controlled trial. [25] | Human trials |
| Semaglutide | No clear effect | Same 100 women with PCOS, 16 weeks: estradiol change 9.01 pg/mL with semaglutide plus metformin vs 9.06 with metformin alone (not significant); chemiluminescence assayAdding semaglutide did not change estradiol beyond metformin alone. [26] | Human trials |
| Thyrotropin-Releasing Hormone (TRH) | No clear effect | Sustained oral dosing. 5 postmenopausal women, 50 mg 4 times a day for 7 days: no estradiol change. 6 menstruating women, 60 mg/day for two cycles: estradiol secretion and ovulation unaffected (radioimmunoassay)Oral TRH did not change estradiol in two small studies. [27] [28] | Human trials |
| Goserelin | Lowers | Women, implant 3.6 mg (sustained). Initial surge: transient increase in estrogen in women with breast cancer. Suppression: estradiol falls to postmenopausal levels within 3 weeks; isolated elevations later in 10% of trial patients; assay not statedA GnRH agonist: estrogen rises briefly, then estradiol falls to postmenopausal levels within about three weeks. [29] | FDA label |
| Leuprolide | Lowers | Lupron Depot label: a transient increase in estrone and estradiol in premenopausal women after the initial LH/FSH surge, then estrogens fall to postmenopausal concentrations within two to four weeks; assay not statedIn premenopausal women estradiol first rises briefly, then falls to postmenopausal levels within two to four weeks. [17] | FDA label |
| Nafarelin | Lowers | Synarel label: a temporary increase of ovarian steroidogenesis at the onset, then decreased secretion of gonadal steroids by about 4 weeks; the label describes it as a drug that lowers serum estradiol (women with endometriosis); assay not statedEstradiol rises briefly at the start, then falls by about 4 weeks of twice-daily use. [30] | FDA label |
| Triptorelin | Lowers | Initial surge: after the first dose "a transient surge in circulating levels of ... estradiol" (Trelstar). Suppression: "by 4 weeks ... marked reduction in sex steroids" (Triptodur). Premenopausal women with breast cancer, 3.75 mg monthly: estradiol down 86.9% on average after 4 weeksA GnRH agonist: estradiol rises briefly after the first injection, then falls steeply within about 4 weeks. [31] [32] [33] | FDA label |
| Irisin | Raises | Kurdish ewes, IV irisin 20 or 40 ng/kg every three days for 45 days (sustained): estrogen rose, particularly on Days 30 and 45, returning near baseline by Day 60; reported as estrogen, assay not statedSheep (Kurdish ewes) only; reported as estrogen. Not studied in people. [34] | Animal studies |
What high or low results can mean
A high result
In women, high estradiol usually reflects the pre-ovulation peak, pregnancy or fertility drugs. In men, high estradiol suggests increased aromatization of androgens.
- Pre-ovulation peak or pregnancy
- Fertility drugs
- Ovarian overactivity
- Increased aromatization in men
- Liver cirrhosis
A low result
Low estradiol is expected after menopause. In younger women it suggests ovarian failure or a pituitary or hypothalamic problem. In men, very low levels harm bone and increase body fat.
- Menopause
- Primary ovarian insufficiency
- Pituitary or hypothalamic disease
- GnRH agonist treatment
- Long-term opioids
How the test works
| Sample | Labcorp's immunoassay takes serum (preferred) or lithium-heparin plasma; its sensitive LC-MS test takes serum only. Quest warns not to add estradiol to a gel-barrier specimen older than 72 hours, because estradiol binds to the gel and reads low. |
|---|---|
| Fasting | Neither Labcorp nor Quest lists a fasting requirement for estradiol. |
| Timing | In women, note the cycle day. For men, children and postmenopausal women, order the sensitive LC-MS/MS test (Labcorp 140244, Quest 30289). Stop high-dose biotin at least 72 hours before immunoassays. |
| Lab differences | Immunoassays are unreliable at the low levels seen in men and postmenopausal women; most of 17 assays compared could not measure below 10 pg/mL. The breast-cancer drug fulvestrant cross-reacts with immunoassays and can give falsely high results, so LC-MS/MS is recommended. Results from different methods should not be used interchangeably. |
| Retesting | Within-person variation for estradiol was about 14% in men. Use the same lab and method for serial tests. |
| Labcorp order code | 004515: Estradiol (immunoassay) |
| Labcorp order code | 140244: Estradiol, Sensitive, LC/MS |
| Quest Diagnostics order code | 4021: Estradiol (immunoassay) |
| Quest Diagnostics order code | 30289: Estradiol, Ultrasensitive, LC/MS |
| LOINC codes |
|
History
Estradiol has been measured in blood since the first radioimmunoassays in 1969. Since 2013, concern about inaccurate low-level results has pushed testing toward mass spectrometry.
- 1969A solid-phase radioimmunoassay of estradiol-17 beta is published. [38]
- 2013The Endocrine Society publishes a position statement on the challenges of measuring estradiol at low levels. [10]
- 2013Finkelstein and colleagues show that estrogen deficiency, not only androgen deficiency, drives body-fat gain in men. [7]
- 2014A comparison of 17 estradiol assays finds high variability and that most cannot measure below 10 pg/mL. [11]
- 2016Estradiol above 10 pg/mL is found generally sufficient to prevent bone loss in men. [8]
- 2019Fulvestrant is shown to cross-react with estradiol immunoassays; LC-MS/MS is recommended for women on it. [36]
FAQ
What is a normal estradiol level for a man?
On sensitive LC-MS/MS tests, 8.0-35.0 pg/mL at Labcorp and 29 or below at Quest. Standard immunoassay ranges are wider (Labcorp 7.6-42.6), and less reliable at these levels.
What is a normal estradiol level for a woman?
It depends on the cycle phase. On Labcorp's sensitive test, follicular 30.0-100.0 and luteal 70.0-300.0 pg/mL; on its immunoassay the ovulation range is 85.8-498.0. After menopause it is below 15.0 on the sensitive test.
Do I need a sensitive estradiol test?
If you are a man, a child or a postmenopausal woman, yes. Both Labcorp and Quest recommend their LC-MS/MS tests when low levels are expected, because immunoassays are unreliable there.
Why do estradiol results differ between labs?
Methods vary a lot: in a comparison of 17 assays only 3 met performance criteria, and most could not measure below 10 pg/mL. Labcorp says results from different methods should not be used interchangeably.
Is the estradiol test HoSt-certified?
We found no CDC HoSt certification claim in Labcorp or Quest estradiol documentation, and CDC's own participant list returned an access-denied error, so it could not be checked.
Why do men need estradiol?
In men estrogen deficiency mainly increased body fat and contributed to lower sexual function, and estradiol above 10 pg/mL was generally enough to protect bone.
What causes high estradiol in men?
Increased aromatization of androgens, which can cause breast growth, and liver cirrhosis. Confirm with a sensitive test first.
Can medications interfere with the estradiol test?
Yes. Fulvestrant cross-reacts with immunoassays and can give falsely high results, and high-dose biotin can disturb immunoassays. LC-MS/MS avoids both.
Does exercise lower estradiol?
Hard training can: 300 minutes a week of vigorous exercise cut total estrogen exposure by 18.9% in premenopausal women, mostly in the luteal phase. A milder 150-minute-a-week program had no effect.
Does hCG raise estradiol?
In men, yes: estradiol peaked 24 hours after the first Human Chorionic Gonadotropin (hCG) injection, 168% above baseline. With longer twice-weekly use the change (27.5 to 32 pg/mL) was not significant.
What do GnRH agonists do to estradiol?
Leuprolide causes a transient increase in estradiol in premenopausal women, then estrogens fall to postmenopausal concentrations within two to four weeks. Triptorelin and Goserelin work the same way.
References
- Labcorp. Test 004515: Estradiol (ECLIA). Use, special instructions, limitations, additional information, specimen requirements, reference range and LOINC map. labcorp.com/tests/004515/estradiol
- Quest Diagnostics. Test code 4021: Estradiol (immunoassay). Test directory entry (East region): clinical significance, collection notes, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/4021/estradiol?cc=PHP
- Labcorp. Test 140244: Estradiol, Sensitive, LC/MS. Use, limitations, specimen requirements and reference ranges. labcorp.com/tests/140244/estradiol-sensitive-lc-ms
- Labcorp. Test 082016: Sex Hormone-binding Globulin. Additional information on SHBG binding of testosterone and estradiol. labcorp.com/tests/082016/sex-hormone-binding-globulin
- Luppa PB, Thaler M, Schulte-Frohlinde E, et al. Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis. Clin Chem Lab Med. 2006;44(8):967-73. PMID 16879062
- Ginsburg ES, Gao X, Shea BF, et al. Half-life of estradiol in postmenopausal women. Gynecol Obstet Invest. 1998;45(1):45-8. PMID 9473164
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-22. PMID 24024838
- Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114-25. PMID 26901812
- Quest Diagnostics. Test code 30289: Estradiol, Ultrasensitive, LC/MS. Test directory entry (East region): methodology, clinical significance, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/30289/estradiol-ultrasensitive-lcms?cc=PHP
- Rosner W, Hankinson SE, Sluss PM, et al. Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab. 2013;98(4):1376-87. PMID 23463657
- Vesper HW, Botelho JC, Vidal ML, et al. High variability in serum estradiol measurements in men and women. Steroids. 2014;82:7-13. PMID 24407040
- Meier C, Christ-Crain M, Christoffel-Courtin C, et al. Serum estradiol after single dose hCG administration correlates with Leydig cell reserve in hypogonadal men: reassessment of the hCG stimulation test. Clin Lab. 2005;51(9-10):509-15. PMID 16285473
- Zucker I, Rainer Q, Pai RK, et al. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022;14(5):e25543. PMID 35800844
- Kossman DA, Williams NI, Domchek SM, et al. Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer. J Appl Physiol (1985). 2011;111(6):1687-93. PMID 21903887
- Smith AJ, Phipps WR, Arikawa AY, et al. Effects of aerobic exercise on premenopausal sex hormone levels: results of the WISER study, a randomized clinical trial in healthy, sedentary, eumenorrheic women. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1098-106. PMID 21467231
- Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3(5):377-84. PMID 14622741
- LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
- Liu Z, Mao J, Wu X, et al. [Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH]. Zhonghua Yi Xue Za Zhi. 2015;95(42):3432-5. PMID 26813133
- Anderson RE, Cragun JM, Chang RJ, et al. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. Fertil Steril. 1989;52(2):216-20. PMID 2502437
- Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351(10):987-97. PMID 15342807
- Faure N, Lemay A. Acute pituitary-ovarian response during chronic luteinizing hormone-releasing hormone agonist administration in polycystic ovarian syndrome. Clin Endocrinol (Oxf). 1988;29(4):403-10. PMID 3150825
- Urbancsek J, Rabe T, Gör U, et al. [Effect of the GnRH analog buserelin on sex hormone serum level in relation to treatment onset and duration]. Geburtshilfe Frauenheilkd. 1991;51(8):617-25. PMID 1834511
- La Vignera S, Cannarella R, Garofalo V, et al. Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reprod Biol Endocrinol. 2025;23(1):92. PMID 40604795
- Prelević GM, Wurzburger MI, Balint-Perić L. The effect of somatostatin analog octreotide (Sandostatin) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion. Gynecol Endocrinol. 1992;6(4):259-63. PMID 1492581
- Galbiati F, Hiranandani S, Wronski ML, et al. Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity. Int J Obes (Lond). 2026;50(7):1508-1514. PMID 41951782
- Chen H, Lei X, Yang Z, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23(1):108. PMID 40713699
- Lee SG, Lundy LE, Kashef M, et al. Influence of thyrotropin-releasing hormone on the postmenopausal female. Obstet Gynecol. 1975;45(1):25-6. PMID 803307
- Lasso P, Zárate A, Soria J, et al. Long-term administration of thyrotropin-releasing hormone and its effect on gonadotropin secretion in eumenorrheic women. Fertil Steril. 1976;27(6):636-9. PMID 819312
- ZOLADEX (goserelin implant), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
- SYNAREL (nafarelin acetate) nasal spray, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6
- TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
- TRIPTODUR (triptorelin) for extended-release injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e
- Celio L, Martinetti A, Ferrari L, et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. 1999;19(3B):2261-8. PMID 10472341
- Shokrollahi B, Sharifi F. Dose- and time-dependent effects of intravenous irisin administration on GnRH, LH, FSH, and estrogen in Kurdish ewes during the breeding season. Res Vet Sci. 2025;193:105737. PMID 40505589
- LOINC 2243-4: Estradiol (E2) [Mass/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/2243-4
- Owen LJ, Monaghan PJ, Armstrong A, et al. Oestradiol measurement during fulvestrant treatment for breast cancer. Br J Cancer. 2019;120(4):404-406. PMID 30679781
- Røys EÅ, Guldhaug NA, Viste K, et al. Sex Hormones and Adrenal Steroids: Biological Variation Estimated Using Direct and Indirect Methods. Clin Chem. 2023;69(1):100-109. PMID 36373220
- Abraham GE. Solid-phase radioimmunoassay of estradiol-17 beta. J Clin Endocrinol Metab. 1969;29(6):866-70. PMID 5783587
Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.